News Details
Annual Congress on Hematologic Malignancies Features Expert Perspectives on Latest Developments in Caring for Persons with Blood Cancers, Including CAR T-Cell Therapy-Related Toxicities, BTKi Inhibitors, Bispecific T-Cell Engagers, Graft-Versus-Host Disease, and More
The NCCN 2023 Annual Congress: Hematologic Malignancies™ returns to San Francisco for the first time since 2019.
The hybrid event will take place live in-person and via virtual livestream Friday, September 22 – Saturday, September 23, 2023.
What: The NCCN Annual Congress: Hematologic Malignancies™ is a certified continuing education event for the entire oncology care team. Leaders in the field will present the latest evidence and expert consensus to improve care for patients with blood cancers. In-person attendees will have additional opportunities to network with experts in hematologic malignancies and each other.
NCCN’s annual gathering features insights from world-renowned experts for determining the optimal evidence-based treatment options for various blood cancers, and how best to protect vulnerable populations in a changing healthcare landscape. Live sessions will take place in-person and remotely through the virtual event platform so all attendees can access interactive presentations, debates, and case study discussions.
Featured topics include:
- Identifying and managing toxicities in patients receiving CAR T-cell therapy
- Revolutionizing hematologic cancer treatment with bispecific T-cell engagers
- Integrating new WHO/ICC classification systems
- Tackling inequities in access and quality of care for patients with multiple myeloma
- Managing Graft-Versus-Host Disease in transplant recipients
- Prevention and management of blood clots
Plus new information pertaining to the treatment of:
- Adult Acute Lymphoblastic Leukemia (ALL)
- Acute Myeloid Leukemia (AML)
- B-Cell Malignancies
- Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
- Chronic Myeloid Leukemia
- Hodgkin Lymphoma
- Mantle Cell Lymphoma (MCL)
- Multiple Myeloma (MM)
- Myelodysplastic Syndromes (MDS)
- Myelofibrosis (MF)
- Waldenström Macroglobulinemia (WM)
When: September 22─23, 2023
Who: The full faculty list includes 30 hematologic malignancy experts from across NCCN Member Institutions. Speakers include physicians, nurses, pharmacists, and patient advocates. The congress will be chaired by Andrew D. Zelenetz, MD, PhD, Memorial Sloan Kettering Cancer Center. Planning committee members include: Gabriela S. Hobbs, MD, Mass General Cancer Center; Shaji K. Kumar, MD, Mayo Clinic Comprehensive Cancer Center; Bernard Marini, PharmD, BCOP, University of Michigan Rogel Cancer Center; and MiKaela Olsen, DNP, APRN-CNS, AOCNS, FAAN, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
Visit NCCN.org/hem for the full agenda including all topics, faculty, and learning objectives.
Media can contact Rachel Darwin at darwin@nccn.org for complimentary press registration.
# # #
About the National Comprehensive Cancer Network
The National Comprehensive Cancer Network® (NCCN®) is a not-for-profit alliance of leading cancer centers devoted to patient care, research, and education. NCCN is dedicated to improving and facilitating quality, effective, equitable, and accessible cancer care so all patients can live better lives. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) provide transparent, evidence-based, expert consensus recommendations for cancer treatment, prevention, and supportive services; they are the recognized standard for clinical direction and policy in cancer management and the most thorough and frequently-updated clinical practice guidelines available in any area of medicine. The NCCN Guidelines for Patients® provide expert cancer treatment information to inform and empower patients and caregivers, through support from the NCCN Foundation®. NCCN also advances continuing education, global initiatives, policy, and research collaboration and publication in oncology. Visit NCCN.org for more information.